Chantal Parpex

LBO France Gestion SAS (LBO France) is one of the oldest independent private equity firms in France. Established in 1985, the firm manages leveraged buyout transactions through their small-cap, mid-cap and real estate funds. Headquartered in Paris, LBO France primarily targets French firms or companies which are based or which transact most of their business in France.

Innovation Capital SASU (Innovation Capital) is the international venture capital subsidiary of CDC Capital Investissement SAS, itself a wholly-owned subsidiary of State-owned CDC Caisse des Dépôts et Consignations in France. Established in 1996 as CDC Entreprises Innovation, the firm was formerly known as CDC Innovation SASU. They changed their name to Innovation Capital SASU in 2012. Located in Paris with representative offices in California and in Switzerland, the firm manages venture capital and innovation mutual funds (FCPRs and FCPIs). Their venture capital funds are sponsored by CDC Capital Investissement, and the innovation funds are generally co-invested with the venture capital funds. The firm's mandate includes public interest missions.

Cytheris SA develops and manufactures drugs for immune modulation. It is a clinical-stage biopharmaceutical company focused on treating lymphopenia driven diseases. The firm's product CYT107 (glycosylated r-hIL-7), is in clinical development for two targeted indications with urgent medical needs and no current treatments: Progressive Multifocal Leukoencephalopathy (PML) in severely lymphopenic patients and Reduction of complications in Immune Non-Responders with HIV controlled by anti-retroviral treatment (HIV-INR). Cytheris has locations in France and The United States. The company was founded in January 1999 by Michel Morre and is headquartered in Issy-les-Moulineaux, France.

Novagali Pharma SA specializes in research, development and marketing of ophthalmic drugs. Their product pipeline includes products at various stages of development, which address diseases encountered at the three different segment levels of the eye which are surface, anterior and posterior segments. Some of these diseases are dry eye, allergy, glaucoma and retinopathies. Their formulations are based on their technology platforms Novasorb and Eyeject, which optimize bioavailability of drugs as well as safety and comfort for the patient. The company was founded on August 8, 2000 and is headquartered in Evry, France.

INSERM Transfert SA is a Venture Capital firm, a subsidiary of Institut National de la Sant? et de la Recherche M?dicale founded in 2000. INSERM Transfert SA is headquartered in Paris, France.

Kayentis SAS provides software in clinical trials solutions. It publishes and operates digital pen and smart paper solutions for the healthcare industry. The firm provides eCOA and eCRF solutions for trial management. It operates through its offices located in Gif-sur-Yvette and Saint Louis. The company was founded by Philippe Berna in 2009 and is headquartered in Gif-sur-Yvette, France.

Bioring SA is a venture-backed company which designs, develops and markets new biodegradable medical devices and implants improving treatment outcome and reducing post treatment risk and complications. The Company's products originate from a proprietary know-how in chemical engineering and manufacturing which results in a unique technology platform combined with an expertise in medical device design and development. The Company's products find applications across the board, with a primary focus on cardiac surgery and urology. They can be implanted in standard open surgery as well as minimally invasive surgery, with or without a catheter. Bioring is funded by CDC Innovation, a leading French venture capital group, in addition to a number of business angels. The Company has taken its first product to the market in cardiac surgery in 2005 and has ongoing developments of other cardiac devices as well as promising urology products. Each one of these products addresses an opportunity of several hundred million dollars. Cardiac surgery The biodegradable Kalangos Rings for mitral and tricuspid valvuloplasty in adults and children is CE marked Cardiology Biodegradable stents for coronary arteries: in development Biodegradable membranes and support for percutaneous patent foramen ovale occlusion: in development Urology Biodegradable stents for male urethral implantation: in development Biodegradable prostheses for female urinary incontinence (FUI): in development